Clinical Trial Update: Ublituximab + Ibrutinib in Select B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating ublituximab in combination with ibrutinib for select B-cell malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED